A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2022-04-22
AEs
3
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-06-22 (study day 46); relationship: Y
moderate
assessed
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-08-06 (study day 91); relationship: not assessed
mild
assessed
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-08-08 (study day 93); relationship: N
Data queries
No data queries.